SynaptixBio, the only company licensed to commercialise a treatment for a rare but deadly disease, says late or missed diagnosis can lead to years of unnecessary suffering Oxford-based SynaptixBio, ...
The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third ...